Ruti Aga: Six Years, and a Prescription No Clinic Ever Wrote

There was a finish line in China in March, and a first place next to Ruti Aga's name. I have no split from that race, no time, no measure of the field's depth — only the record of a win. What I do have comes after it: an in-competition sample, and a prescription the Athletics Integrity Unit dismantled from three separate directions. The "doctor" on the paper turned out to be a family member with no medical registration. The clinic named on the paper did not exist. Asked where the document came from, the answer was an "old prescription pad left behind at a former workplace" — a pad the clinic explicitly disowned. This time I traced a prescription, not a javelin.

The arithmetic is where the case lives. Two years for the presence of a prohibited substance, four years for tampering and misleading an investigator. Six years in total, counted from 10 September, the same date her provisional suspension began. At 32, that arithmetic says only one thing: she will be roughly 38 when the ban ends, and Ethiopia's women's marathon depth leaves no selection slot for a 38-year-old with a document case attached.

Context: the substance class, and the error everyone repeated

Start with the record. Aga's name was built on the 2026 Tokyo Marathon title and three second places at World Marathon Majors — a 2:18–2:20 performer who was a regular Major podium contender, never a championship medallist. The 2:18:34 from Berlin 2026 and 2:20:40 from Tokyo 2026 sit in my own file, not in the AIU statement; treat them as pending verification. What the statement does contain: a sample after winning a half marathon in China in March, methylprednisolone present, a knee-injury explanation, a forged prescription.

Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, WADA Prohibited List class S9. Under the current List, S9 substances are prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection out of competition is entirely legal; it becomes a violation only if residues are present in competition. The hinge of this case is therefore route and timing, not "steroid use" — the technical point most coverage skipped, and the one a defence could have been built on.

Core: two plus four, and a document that failed three checks

The sanction architecture is standard, not exceptional. Two years for presence — the usual outcome when a substance is specified and intent is not proven — and four years for tampering, the Code's default. The sum tells you the panel rejected the no-significant-fault mitigation. With genuine medical records, the presence charge could have been argued at the no-fault end and no tampering charge would have existed at all. What she did was destroy the one defence that could have worked.

Look at the three verification failures separately. One: a family member with no registration signed as doctor. Two: the clinic named on the prescription does not exist. Three: the "old prescription pad" explanation, publicly denied by the clinic. Three independent failures, not three versions of one mistake. That is why the tampering charge rests on statements made in interview rather than on the document alone.

One deliberately qualitative column belongs here. The knee-injury story is mechanistically plausible — intra-articular or peri-articular methylprednisolone for knee synovitis is ordinary sports medicine in distance runners. That plausibility is exactly what makes the forgery decisive: a real treatment would have been defended with real paper. This is not one runner's lapse; it is the failure of the medical governance she operates inside. No credentialed team physician named, no TUE application, no washout calculation. East African road-running entourages are routinely exposed at this exact point, and the clustering of AIU tampering cases is the same crack seen from a different angle.

The economics sharpen it. Aga's post-2026 calendar was selective Majors plus Asian label races — the classic low-race-count, high-appearance-fee model for a 2:18–2:20 marathoner. China's label circuit is the thick, low-risk income tier between Majors for East African runners. It is also now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races, and the athlete pays the bill, not the organiser.

Contrarian: six years for a substance with no proven endurance benefit

An uncomfortable fact has to be entered. Glucocorticoids have no established performance benefit in endurance events — they reduce inflammation and mask pain, which makes them the cheapest available tool for hiding injury. The six years is not for the substance; it is for the forgery. Those who will cite this as proof of AIU rigour and those who will cite it as uneven enforcement against African road runners will both pull the same number their way. My position is plain: this is a case about document integrity, not substance load, and document integrity is not a continental question.

The opposite error is reading the win as form. No time from that March half marathon appears in the source. Against the current world records — 57:30 mixed, 65:18 women-only — no gap can be computed, because the baseline is missing. "Won" tells us only that a label-tier elite field was there and in-competition testing happened. Anything beyond that is invention. The source also does not state that the result and prize money were annulled, although AIU practice voids the competition where the sample was collected; that is inference, labelled as inference. What does not move is the 2026 Tokyo title: earlier results are not automatically annulled absent a finding of earlier use.

Takeaway: what to check by morning

First, the CAS window — typically about 21 days from the reasoned decision, live but low-value, because a document-based finding is hard to overturn. Second, the Ethiopian federation's silence: not one national-level sentence is quoted in the statement, only the AIU. Third, the question nobody has asked — who advised the forgery, and was the agent or management ever in scope. I do not trust a trend until I can reconcile it to the ledger. One trend does reconcile here: the next East African road-running case will not begin with a substance. It will begin with a piece of paper.